Vandana Abramson is Professor of Medicine, Division of Hematology and Oncology; Donna S. Hall Chair in Breast Cancer; Co-Leader, Breast Cancer Research Program. OpenAlex indexes 444 publications with 12,028 citations (h-index 50); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Updated 20 Oct 2026
Vandana Abramson, MD, is Professor of Medicine, Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center. The public record shows 444 publications with 12,045 citations (h-index 50), centered on Breast Cancer Treatment Studies, Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 11 companies, 2 NIH-funded awards (2010–2026).
- Most recent indexed publication: 2026 · Journal of the National Cancer Institute
- Top research focus: Breast Cancer Treatment Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 20 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 102.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 37232-0021
Telephone
615-936-2000Provider last certified this registry record 23 Mar 2022 · collected 28 Jul 2026.
Clinical trials
Updated 20 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Sponsor: Vandana Abramson
- TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Sponsor: Ana C Garrido-Castro, MD
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Industry payments
Updated 20 Oct 2026
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202523 payments$44,172openpaymentsdata.cms.gov ↗
- Samsung Bioepis Co., Ltd.Program year20255 payments
- Genentech USA, Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor62.3%Ibrance80%Kisqali20%Part D<11 patientsAromatase Inhibitor30.1%Letrozole68%Anastrozole32%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 20 Oct 2026
2 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Improving Outcomes for Patients with Triple-Negative Breast Cancer
Vanderbilt University Medical Center
FY2026$400,313R01CA312128 - Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
Vanderbilt University Medical Center
FY2018$461,172U01CA142565 - Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
Vanderbilt University Medical Center
FY2017$461,999U01CA142565
Congress activity
Updated 20 Oct 2026
69 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- ASPRIA: A single-arm phase 2 trial of atezolizumab with sacituzumab govitecan to prevent recurrence in triple-negative breast cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 20 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Journal of the National Cancer Institute
Clinical Trial2026 - Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Cancer research communications
Article2024
Most-cited works
by citation count (OpenAlex)- 01Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerArticle1,323 citations2019
- 02Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerArticle870 citations2019
- 03Phase II Trial of Sorafenib in Advanced Thyroid CancerArticle680 citations2008
- 04Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyArticle667 citations2024
- 05
Network
Updated 20 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 20 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
podcast.ausha.co/duologue-with-leslie-heaney/nothing-but-the-breast-feat-vandana-abramson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcast.ausha.co ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 20 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- BA in English and Molecular & Cell Biology
University of California, Berkeley
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.vumc.org ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →news.vumc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”